Trial Profile
Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2015
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Phalcis
- 06 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 30 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 11 May 2011 Planned End Date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.